Previous Close | 5.5 |
1-Year Change | -22.75% |
6-Months Change | 7.42% |
3-Months Change | 38.54% |
Moving Avg (50d) | 5.9738 |
Moving Avg (200d) | 5.4782 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 447.7M |
Beta (3-Years) | 1.93 |
Revenue Growth (ttm) | % |
Net Profit Margin (ttm) | 50.65% |
Return On Assets (ttm) | -32.73% |
EPS (ttm) | -0.65 |
PE Ratio (ttm) | -8.46 |
Dividend Yield | % |
Asset Description: | Anavex Life Sciences Corp. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-08-28 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
5.61 | 5.775 | 5.885 | 6.05 | 6.325 | 6.6 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |